Prevention, Monitor and management of HBV drug-resistance

( views:, downloads: )
Journal Title:
Volume 1, Issue 01, 2008
Key Word:


  • [1]Locarnini S.Molecular virology and the development of resistant mutants:implications for therapy.Semin Liver Dis,2005,25(Suppl 1):9-19.
  • [2]Lok AS,Zoulim F,Locarnini S,et al.Antiviral drug-resistant HBV:standardization of nomenclature and assays and recommendations for management.Hepatology,2007,46(1):254-265.
  • [3]Lok ASF,McMahon BJ.AASLD practice guidelines:Chronic hepatitis B.Hepatology,2007,45(2):507-539.
  • [4]Hoofnagle JH,Doo E,Liang TJ,et al.Management of hepatitis B:Summary of a clinical research workshop.Hepatology,2007,45(4):1056-1075.
  • [5]Keeffe EB,Zeuzem S,Koff RS,et al.Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B.Clin Gastroenterol Hepatol,2007,5 (8):890-897.
  • [6]Lok AS,Heathcote EJ,Hoofnagle JH.Management of hepatitis B:2000-summary of a workshop.Gastroenterology,2001,120(7):1828-1853.
  • [7]EASL Jury.EASL International Consensus Conference on Hepatitis B.13-14 September,2002:Geneva,Switzerland.Consensus statement(short version).J Hepatol,2003,38(4):533-540.
  • [8]Liaw YF,Leung N,Guan R,et al.Asian-Pacific consensus statement the management of chronic hepatitis B:a 2005 update.Liver Int,2005,25(3):472-489.
  • [9]Chevaliez S,Pawlotsky JM.Use of virologic assays in the diagnosis and management of hepatitis C virus infection.Clin Liver Dis,2005,9(3):371-382.
  • [10]Lopez VA,Bourne EJ,Lutz MW,et al.Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels.J Clin Microbiol,2002,40(6):1972-1976.
  • [11]Lindh M,Hannoun C.Dynamic range and reproducibility of hepatitis B virus(HBV)DNA detection and quantification by Cobas Taqman HBV,a real-time semiautomated assay.J Clin Microbiol,2005,43(8):4251-4254.
  • [12]Keeffe EB,Dieterich DT,Han SH,et al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United states:an update.Clin Gastroenterol Hepatol,2006,4(8):936-962.
  • [13]Chen CJ,Yang HI,Su J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA,2006,295(1):65-73.
  • [14]Iloeje UH,Yang HI,Su J,et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.Gastroenterology,2006,130(3):678-686.
  • [15]Chen G,Lin W,Shen F,et al.Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.Am J Gastroenterol,2006,101(8):1797-1803.
  • [16]Liaw YF.Hepatitis B virus replication and liver disease progression:the impact of antiviral therapy.Antivir Ther,2006,11(6):669-679.
  • [17]Chen YC,Chu CM,Yeh CT,et al.Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a long-term follow-up study.Hep Intl,2007,1(1):267-273.
  • [18]Yang HI,Lu SN,Liaw YF,et al.Hepatitis B e antigen and the risk of hepatocellular carcinoma.N Ensl J Med,2002,347(3):168-174.
  • [19]Yuen MF,Sablon E,Libbrecht E,et al.Significance of viral load,core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.Antivir Ther,2006,11(6):779-786.
  • [20]Locarnini S,Hatzakis A,Heathcote J,et al.Management of antiviral resistance in patients with chronic hepatitis B.Antivir Ther,2004,9(5):679-693.
  • [21]Perrillo RP,Gish RG,Peters M,et al.Chronic hepatitis B:a critical appraisal of current approaches to therapy.Clin Gastroenterol Hepatol,2006,4(2):233-48.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615